We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly
efficient in their ability to recruit C1q to the surface of CD20-positive cells and mediate …

Despite the rapid and widespread integration of chimeric CD20 monoclonal antibody (mAb),
rituximab, into the management of non-Hodgkin lymphoma, its efficacy remains variable …

Signaling through the pre-TCR is essential for early T cell development and is severely
impaired in mice lacking the CD3γ chain of the pre-TCR. We here address the molecular …

We evaluated the dose requirements for sustained in vivo activity of ofatumumab, a human
anti‐CD20 antibody under development for the treatment of B cell‐mediated diseases. In a …

Tetraspanin CD37 has recently received renewed interest as a therapeutic target for B-cell
malignancies. Although complement-dependent cytotoxicity (CDC) is a powerful Fc-mediated …

Background HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that
binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural …

Ab-dependent cellular cytotoxicity (ADCC) is recognized as a prominent cytotoxic mechanism
for therapeutic mAbs in vitro. However, the contribution of ADCC to in vivo efficacy, …

The immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains associated
with the T cell receptor (TCR) are crucial for TCR signaling. To probe the role of the CD3γ–…

At least four different CD3 polypeptide chains are contained within the mature TCR complex,
each encompassing one (CD3γ, CD3δ, and CD3ε) or three (CD3ζ) immunoreceptor tyrosine…

Longitudinal imaging of intratumoral distributions of antibodies in vivo in mouse cancer models
is of great importance for developing cancer therapies. In this study, multipinhole SPECT …